Dmitry Medvedev presents national first "Industry" price Biocad -
On July 9, Prime Minister of the Russian Federation Dmitry Medvedev presented the first national "Industry" price from Russia to Russia Biocad a biopharmaceutical company. The company develops a unique project called MabNext. Under the MabNext Biocad project is developing a number of innovative drugs based on monoclonal antibodies for the treatment of cancer and autoimmune diseases. The ceremony took place at the International Exhibition "INNOPROM 2014" in Ekaterinburg.
According to the Russian Ministry of Health, over the last 12 years, the number of new cases of malignant tumors increased by 11%. The constantly increasing number of cancer patients is a global trend. According to the International Agency for Research on Cancer, over the next 20 years, the number of new cancer patients in the world will rise to 22 million cases per year. Consequently, Russia and the rest of the world are so desperate for new effective drugs that will help overcome serious diseases and save millions of lives.
Biocad develops a wide range of innovative products based on monoclonal antibodies for the treatment of diseases such as breast cancer, colorectal cancer, lung cancer, melanoma, multiple sclerosis, rheumatoid arthritis and psoriasis.
"Today, the country is undergoing fundamental changes with regard to the availability of modern medicines for its people. Thanks to the support of the Ministry of Industry and Trade, Ministry of Health, Ministry economic development, the Russian pharmaceutical companies create a strong technological basis for the production of innovative products and compete successfully in the global pharmaceutical market. of course, our foreign colleagues are not happy with this. However, we can now provide innovative medicines which have no analogues in the world. MabNext the project is a shining example of this, "said Dmitriy Morozov, CEO of Biocad.
The main advantage of monoclonal antibody-based products is that they affect cells or selected molecules, in other words, these therapies are targeted. Only the relevant targets are neutralized without affecting healthy cells.
Biocad has over 10 of these innovative products based on monoclonal antibodies at various stages of development. One of the most notable is an antibody specific for interleukin 17. Clinical trials of this drug will begin in 2014. The drug has no analogues in the market and its characteristics are superior to anti-IL17 antibodies in the process of development by foreign companies. This product has huge potential as regards the treatment of socially significant diseases such as rheumatoid arthritis and psoriasis
If we talk about cancer -. The company is at the stage of development of original products based on monoclonal antibodies against targets such as PD-1, Ang-2 HER3 and others. PD-1 antibody to increase the patient's immune system's ability to recognize and destroy tumor cells.
EmoticonEmoticon